Author: ALLISON GATLIN
Source
TG Therapeutics stock rose Wednesday after the company unveiled promising five-year test results for its multiple sclerosis drug, Briumvi.
The post IBD 50’s TG Therapeutics Rises On Five-Year Data For Multiple Sclerosis Drug appeared first on Investor’s Business Daily.